
    
      The study design is based on a phase I trial in Spanish.

      A number of 16 patients will be included to assess the safety and maximum tolerated
      dose-level of donor regulatory enriched T cell (Treg) in steroid-refractory chronic graft
      versus host disease (cGVHD) patients who did not obtain complete remission under treatment
      with ruxolitinib.
    
  